

Références bibliographiques par ordre alphabétique

Adler C, Gunzelmann T, Machold C, Schumacher J, Wilz G. Perception of stress by caregiving relatives of dementia patients. *Z Gerontol Geriatr* 1996 ; 29 : 143-9.

Aguero-Torres, H., Fratiglioni, L. et al. Mortality from dementia in advanced age : a 5-year follow-up study of incident dementia cases. *JAGS*, 1999, 46.

Aguero-Torres, H., Fratiglioni, L. et al. Prognostic factors in very old demented patients : a seven-year follow-up from a population-based survey in Stockholm, *JAGS*, 1998, 46, p.444.

Alexopoulos GS, Streim J, Carpenter D, Docherty JP. Using antipsychotic agents in older patients. *J Clin Psychiatry* 2004;65(suppl 2):5-99.

Andrew, MK, Minitski, AB, Rockwood, K. Social vulnerability, frailty and mortality in elderly people. Open access, 2008, 3(5), e2232, www.plosone.org. doi:10.1371/journal.pone.0002232.g001.

Arcand, M., Hébert, R. Précis pratique de gériatrie. Edisem-Maloine (Eds). 2007.

Auchus AP, Bissey-Black C. Pilot study of haloperidol, fluoxetine, and placebo for agitation in Alzheimer's disease. *J Neuropsychiatry Clin Neurosci*. 1997;9:591-593.

Audet, T., D'Amours, M. Déclin cognitive et sécurité routière. Comment évaluer les capacités à conduire ? In Desrosiers, J., Kouri, K. (Eds). *Réadaptation des personnes âgées*, Edisem ; 2001, 50-62.

Bains J, Birks JS, Dening TR. The efficacy of antidepressants in the treatment of depression in dementia. *Cochrane Database Syst Rev* 2002;(4):CD003944.

Bains J, Birks JS, Dening TR. The efficacy of antidepressants in the treatment of depression in dementia. *Cochrane Database Syst Rev*. 2002;4:CD003944.

Ballard C, Grace J, McKeith I, Holmes C. Neuroleptic sensitivity in dementia with Lewy bodies and Alzheimer's disease. *Lancet*. 1998;351:1032-1033.

Ballard CG, O'Brien JT, Reichelt K, Perry EK. Aromatherapy as a safe and effective treatment for the management of agitation in severe dementia: the results of a double-blind, placebo-controlled trial with Melissa. *J Clin Psychiatry*. 2002;63:553-558.

Baskys A. Lewy body dementia: the litmus test for neuroleptic sensitivity and extrapyramidal symptoms. *J Clin Psychiatry*. 2004;65(suppl 11):16-22.

Beauchemin, J.P. Des troubles cognitifs? Oui, mais lesquels? *Le Clinicien*, 1998;13:1 19-37

Bedard M, Kuzik R, Chambers L, Molloy DW, Dubois S, Lever JA. Understanding burden differences between men and women caregivers : the contribution of care-recipient problem behaviours. *Int Psychogeriatr* 2005 ; 17 : 99-118.

Beeri MS, Werner P, Davidson M, Noy S. The cost of behavioral and psychological symptoms of dementia (BPSD) in community dwelling Alzheimer's disease patients. *Int J Geriatr Psychiatry*. 2002;17:403-408.

Bélisle, C., Rivard, B. (2007). *La démence de type Alzheimer et les autres atteintes cognitives*. Formed (ed.), Trois-Rivières.

- Belmin, J. Practical guidelines for the diagnosis and management of weight loss in Alzheimer's disease : a consensus from appropriateness ratings of a large expert panel. *Nutr Health Aging*, 2007, 11(1), 33-37.
- Benoit M, Arbus, Blanchard F, Camus V, Ceerese V, Clément J-P, Frémont P, Guérin O, Hazif-Thomas C, Jeanblanc F, Lafont C, Moreaud O, Pédra M, Poncet M, Richar-Harston S, Rigaud A-S, Soto-Martin M-E, Touchon, J, Vellas B, Fitten L-J, Robert P. Concertation professionnelle sur le traitement de l'agitation, de l'agressivité, de l'opposition et des troubles psychotiques dans les démences. *La Revue de Gériatrie, Tome 31, N°9 NOVEMBRE*, 2006, pp 689-96.
- Berg, K. Balance and it's measure in the elderly: a review. *Physiothérapie Canada*. 41, 5, 240-246.
- Bergman, H. Fragilité, comorbidité et incapacité : le défi d'optimiser la santé et l'état fonctionnel des personnes âgées. *L'Actualité médicale, décembre*, 2006.
- Bergman, H., Hogan, D., Karunanathan, S. La fragilité. Dans *Précis pratique de gériatrie*, Arcand & Hébert, Edisem-Maloine Eds, pp. : 83-91. 2007.
- Bernabei, R. *Community care in Europe. The Aged in Home Care project (AdHOC)*. *Aging Clin Exp Res* 16[4] : 2004, p. 259-269.
- Björkgren, M.A., Fries, B.E., Shugarman, L.R. *A RUG-III based case-mix system for home care*. *Can J Aging* 19[suppl. 2] :2000, p. 106-125.
- Bocquet, H, S. Andrieu. «Le «Burden» : un indicateur spécifique pour les aidants familiaux». *Gérontologie et Société*, no 89, 1999, p. 155-166.
- Boersma, F. et al. (Survival in a population-based cohort of dementia patients: predictors and causes of mortality. *Int. J. Geriatr. Psychiatry*, 1999, 14. 748-53.
- Borson S, Raskind MA. Clinical features and pharmacologic treatment of behavioral symptoms of Alzheimer's disease. *Neurology*. 1997;48(5 suppl 6):S17-S24.
- Botez-Marquard, T. Boller, F. *Neuropsychologie clinique et neurologie du comportement*. Les Presses de l'Université de Montréal, 2005.
- Bouras, EP, Lange, SM, Scolapio, JS. Rational approach to patients with unintentional wight loss. *Mayo Clin Proc*, 2001, 76, 923-929.
- Bracco, L. et al. Factors affecting course and survival in Alzheimer's disease: A 9-year longitudinal study. *Arch. Neurol.*, 1994, 51. 1213-19.
- Bradford. JM. The neurobiology, neuropharmacology, & pharmacological treatment of the paraphilias & compulsive sexual behaviour. *Can J Psychiatry* 2001 Feb;46(1):26-34.
- Breier. A, Meehan, K, Birkett, M, David S, Ferchland I, Sutton V, et al. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. *Arch Gen Psychiatry* 2002;59:441-8.
- Brodaty H, Ames D, Snowdon J, et al. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. *J Clin Psychiatry*. 2003;64:134-143. 29.
- De Deyn PP, Carrasco MM, Deberdt W, et al. Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease. *Int J Geriatr Psychiatry*. 2004;19:115-126.
- Brodaty, H. *Interventions with caregivers*. <http://malattiemetaboliche.it/articoli/vol4no4a.htm>.

- Desai, A.K., Grossberg, G.T. Recognition and Management of Behavioral Disturbances in Dementia. *Primary Care Companion J Clin Psychiatry*, 3, (3), 2001, p. 93-109.
- Devanand, D.P. The interrelations between psychosis, behavioral disturbance, and depression in Alzheimer disease. *Alzheimer Dis Assoc Disord, Nov;13 Suppl 2*, S3-8, 1999.
- Donaldson C, Tarrier N, Burns A. Determinants of carer stress in Alzheimer's disease. *Int J Geriatr Psychiatry*. 1998;13:248-256.
- Doody RS, Stevens JC, Beck C, Dubinsky RM, Kaye JA, Gwyther L, et al. Practice parameter: management of dementia (an evidence-based review). *Neurology*, 2001;56:1154-66.
- Doody RS, Stevens JC, Beck C, et al. Practice parameter: management of dementia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology*. 2001;56:1154-1166.
- Doraiswamy, P.M. et al. Prevalence and impact of Medical Comorbidity in Alzheimer's. *J. Geront. A. Biol. Sci. Med. Sci.*, 2002, 57. M73-77.
- Drevets WC, Rubin EH. Psychotic symptoms and the longitudinal course of senile dementia of the Alzheimer type. *Biol Psychiatry* 1989;25: 39-48.
- Dubinski, RM, Stem AC, Lyons K. Practice parameter: risk of driving and Alzheimer's disease (an evidence-based review): report of the quality standards subcommittee of the American Academy of Neurology. *Neurology*, 2000;54(12):2205-11.
- Dunkin JJ, Anderson-Hanley C. Dementia caregiver burden : a review of the literature and guidelines for assessment and intervention. *Neurology* 1998 ; 51 (Suppl. 1) : S53-S60 ; S65-67.
- Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. *Lancet*. 2002;359:1283-1290.
- Faxen-Irving, G, Andren-Olsson, B, Geijerstam, A, Basun, H, Cederholm, T. The effect of nutritional intervention in elderly subjects residing in group-living for the demented. *Eur J Clin Nutr*, 2002, 56, 221-227.
- Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease [published correction appears in *Neurology* 2001;57:2153]. *Neurology*, 2001;57:613-20.
- Field, T.S. et al. Adverse drug events resulting from patients errors in older adult. *J. Am. Geriatric Soc.*, 2007, 55, 2, 271-76.
- Finkel SI, Mintzer JE, Dysken M, Krishnan KR, Burt T, McRae T. A randomized, placebo-controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestations of Alzheimer's disease in outpatients treated with donepezil. *Int J Geriatr Psychiatry*. 2004;19:9-18.
- Finkel SI. Behavioral and psychological symptoms of dementia: a current focus for clinicians, researchers, and caregivers. *J Clin Psychiatry*. 2001;62(suppl 21):3-6.
- Fletcher, P.C, Hirdes, J.P. Restriction in activity associated with fear of falling among community-based seniors using home care services. *Age Ageing*. 33[3], 2004, p. 273-279.

Fletcher, P.C., Hirdes, J.P. Risk factors for falling among community-based seniors using home care services. *J Gerontol A Biol Sci Med Sci.* 57[8], M504-150, 2002.

Fries B.E, James M, Hammer S.S, Shugarman LR, Morris J.N. Is telephone screening feasible? Accuracy and cost-effectiveness of identifying people medically eligible for home- and community-based services. *Gerontologist* 44[5], 2004, p. 680-688.

Geldmacher DS. Contemporary diagnosis and management of Alzheimer's disease. Newtown, Pa.: Handbooks in Health Care, 2001.

Gerdner LA. Effects of individualized versus classical "relaxation" music on the frequency of agitation in elderly persons with Alzheimer's disease and related disorders. *Int Psychogeriatr.* 2000;12:49-65.

Gillette-Guyonnet S, Nourhashemi F, Andrieu S, de Glisezinki I, Ousset PJ, Rivière D, et al. Weight loss in Alzheimer disease. *Am J Clin Nutr* 2000 ; 2 : 637S-642S.

Gitlin, L.N., Schinfeld, S., Winter, M. Corcoran, M., Boyce, A.A., Hauck, W. Evaluating home environments of persons with dementia: interrater reliability and validity of the Home Environmental Assessment Protocole (HEAP). *Disability and Rehabilitation*, 24, 1-2-3, 2002, 59-71.

Gonthier R, Blanc P, Farce S, Stierlam F. Individualisation des personnes âgées fragiles et filière de soins. *Psychol NeuroPsychiatr Vieill* 2003 ; 1 : 187-96.

Greenspan A, Eerdeken M, Mahmoud R. Is there an increased rate of cerebrovascular events among dementia patients? Poster presented at: 24th Congress of the Collegium Internationale Neuro-Psychopharmacologicum (CINP); June 20-24, 2004; Paris, France.

Guyonnet S, Nourhashemi F, Ousset P, de Glisezinski I, Rivière D, Albarède J, et al. Maladie d'Alzheimer et nutrition. *Rev Neurol (Paris)* 1999 ; 5 : 343-9.

Ham RJ. Confusion, dementia and delirium. In: Primary care geriatrics : A case-based approach. 3rd ed., St-Louis, Mosby, 1997:217-59

Hébert, R., Tourigny, A, Gagnon, M. Programme de recherche sur l'intégration des services de maintien à l'autonomie (PRISMA): Intégrer les services pour le maintien de l'autonomie des personnes. Edisem, 2004.

Hébert, R., Tourigny, A. Programme de recherche sur l'intégration des services de maintien à l'autonomie (PRISMA): Volet II, FCRSS. 2007.

Hirdes, J.P, Fries, B.E, Morris, J.N, Ikegami, N., Zimmerman, D., Dalby, D.M, Aliaga, P., Hammer, S., Jones, R. *Home care quality indicators (HCQIs) based on the MDSHC.* *Gerontologist* 44[5], 2004, 665 à 679.

Hogan DB, Maxwell CJ, Fung TS, Eby EM. Prevalence and potential consequences of benzodiazepine use in senior citizens: results from the Canadian Study of Health and Aging. *Can J Clin Pharmacol.* 2003;10:72-77.

Holmes C, Hopkins V, Hensford C, MacLaughlin V, Wilkinson D, Rosenvinge H. Lavender oil as a treatment for agitated behaviour in severe dementia: a placebo controlled study. *Int J Geriatr Psychiatry.* 2002;17:305-308.

Holmes C, Wilkinson D, Dean C, et al. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. *Neurology.* 2004;63:214-219.

Holtzer R, Tang MX, Devanand DP, Albert SM, Wegesin DJ, Marder K, et al. Psychopathological features in Alzheimer's disease: course and relationship with cognitive status. *J Am Geriatr Soc* 2003;51:953-60. http://www.tbs-sct.qc.ca/pubs_pol/dcgpubs/RiskManagement/rm-rcbp1_f.asp#_toc463080609.

Huang, CY. Informal female caregivers of older adults with dementia in Taiwan. *Calif j Health Promot*, 2004, 2(3), 53-66.

Inoué, S.K. et al. Clarifying confusion : The Confusion Assessment Method. *Annals of Internal Medicine*, 1990, 113, 12, 941-948.

INPES. *Prévention des chutes chez les personnes âgées à domicile. Référentiel de bonnes pratiques. Réseau francophone de prévention et de promotion de la sécurité.* France, sous la direction de H. Bourdesol et L. Pin. INPES (Ed.), 2005.

Institut national de santé publique. *La prévention des chutes chez les aînés : Intervention multifactorielle personnalisée, volet soutien à domicile. Guide d'implantation.* Québec. 2006.

Isaac, L.M., Tamblyn, R.M. Compliance and cognitive function: a methodological approach to measuring unintentional errors in medication compliance in the elderly. McGill-Calgary Drug Research Team. *The Gerontologist, Vol 33, Issue 6.*, 1993, 772-781.

Jerrom B, Mian I, Rukanyake NJ, Prothers D. Stress on relatives caregivers of dementia sufferers and predictors of breakdown of community care. *Int J Geriatr Psychiatry* 1993 ; 8 : 331-7.

Jeste DV, Rockwell E, Harris MJ, Lohr JB, Lacro J. Conventional vs. newer antipsychotics in elderly patients. *Am J Geriatr Psychiatry* 1999;7:70-6.

Katz IR, Jeste DV, Mintzer JE, Clyde C, Napolitano J, Brecher M. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. *J Clin Psychiatry* 1999;60:107-15.

Kergoat, M-J., Légaré, J. Aspects démographiques et épidémiologiques du vieillissement au Québec. Dans *Précis pratique de gériatrie*, Arcand & Hébert, Edisem-Maloine Eds, 2007, pp. : 1-16.

Klein C, Gordon J, Pollak L, Rabey JM. Clozapine in Parkinson's disease psychosis: 5-year follow-up review. *Clin Neuropharmacol* 2003;26:8-11.

Koehler, M., Rabinowitz, T., Hirdes, J.P., Stones, M., Carpenter, G.I., Fries, B.E., Morris, J.N., Jones, R.N. Measuring depression in nursing home residents with the MDS and GDS: an observational psychometric study. *BMC Geriatr* 5[1]: 2005,1.

Kunik, M.E., Huffman, J.C., Bharani, N., Hillman, S.L., Molinari, V.A., Orengo, C.A. Behavioral disturbances in geropsychiatric inpatients across dementia types. *J Geriatr Psychiatry Neurol Spring;13(1),2000*, 49-52.

Lach, H.W., Reed, A.T., Smith, L.J., Carr, D.B. Alzheimer's Disease: Assessing safety problems in the home. *Geriatric Nursing, July-Aug.*, 1995, 160-62.

Lackner TE. Strategies for optimizing antiepileptic drug therapy in elderly people. *Pharmacotherapy* 2002;22:329-64.

Lagnaoui R, Moore N, Moride Y, Miremont-Salame G, Begaud B. Benzodiazepine utilization patterns in Alzheimer's disease patients. *Pharmacoepidemiol Drug Saf* 2003;12:511-5.

Landi F., Onder G., Cesari, M., Barillaro, C., Lattanzio, F., Carbonin, P.U., Bernabei, R. Comorbidity and social factors predicted hospitalization in frail elderly patients. *J. Clin Epidemiol.*, 2004, 57[8], 832-836.

- Landi, F., Lattanzio, F., Gambassi, G., Zuccala, G., Sgadari, A., Panfilo, M., Ruffilli, M.P., Bernabei, R. A model for integrated home care of frail older patients: the Silver Network project. *Aging* 11[4], 1999, 262-272.
- Landi, F., Onder, G., Cattel, C., Gambassi, G., Lattanzio, F., Cesari, M., Russo, A., Bernabei, R., Silvernet-HC Study Group. Functional status and clinical correlates in cognitively impaired community-living older people. *J Geriatr Psychiatry Neurol* 14[1], 2001, 21-27.
- Landi, F., Tua, E., Onder, G., Carrara, B., Sgadari, A., Rinaldi, C., Gambassi, G., Lattanzio, F., Bernabei, R. SILVERNET-HC Study Group. *Minimum Data Set for Home Care: a valid instrument to assess frail older people living in the community*. *Med Care* 38[12] : 2000, 1184 à 1190.
- Lebel P, Leduc N, Kergoat MJ, Latour J, Leclerc C, Beland F. Un modèle dynamique de fragilité. *L'année gérontologique* 1999 ; 13 : 84-94.
- Lebert, F. La gestion des troubles psycho-comportementaux. *La Revue de Gériatrie. Tome 30, supplément A au n°4, avril, A-29 – A-36*. 2005.
- Leipzig RM, Cumming RG, Tinetti ME. Drugs and falls in older people: a systematic review and meta-analysis: I. Psychotropic drugs. *J Am Geriatr Soc*, 1999;47:30-9.
- Leroi I, Voulgari A, Breitner JC, Lyketsos CG. The epidemiology of psychosis in dementia. *Am J Geriatr Psychiatry* 2003;11:83-91.
- Levitsky AM, Owens NJ. Pharmacologic treatment of hypersexuality and paraphilias in nursing home residents. *J Am Geriatr Soc* 1999 Feb;47(2):23 1-4.
- Levy et al. Neuropsychiatric symptoms and cholinergic therapy for alzheimer's disease, *Gerontology*, 45(suppl.), 1999, 15-22.
- Lim, J-W., Zebrack, B. «Caring for family members with chronic physical illness : A critical review of caregiver literature». *Health and Quality of Life Outcomes*, 2(1), 2004, p. .50-59.
- Lonergan E, Luxenberg J, Colford J. Haloperidol for agitation in dementia. *Cochrane Database Syst Rev*. 2002;2:CD002852.
- Lund Manchester Group. Clinical and neuropathological criteria for fronto-temporal dementia. *J Neurol Neurosurg Psychiatry* 1994;57:41 6-18.
- Lyketsos CG, DeCampo L, Steinberg M, et al. Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. *Arch Gen Psychiatry*. 2003;60:737-746.
- Lyketsos CG, Lee HB. Diagnosis and treatment of depression in Alzheimer's disease: a practical update for the clinician. *Dement Geriatr Cogn Disord*. 2004;17:55-64.
- Lyketsos CG, Lopez O, Jones B, Fitzpatrick AL, Breitner J, DeKosky S. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the Cardiovascular Health Study. *JAMA*. 2002;288:1475-1483.
- Lyketsos CG, Steinberg M, Tschanz JT, Norton MC, Steffens DC, Breitner JC. Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging. *Am J Psychiatry*. 2000;157:708-714.

- Mace NL, Rabins PV. *The 36-hour day: a family guide to caring for persons with Alzheimer disease, related dementing illnesses, and memory loss in later life*. 3rd ed. Baltimore: Johns Hopkins University Press, 1999.
- Macera C.A., Eaker, E.D., Jannarone, R.J., Davis, D.R., Stoskopf CH. A measure of perceived burden among caregivers. *Eval Health Prof* 1993 ; 16 : 205-11.
- Maisondieu J. Les familles confrontées aux états démentiels. In Angel P, Mazet P, eds. *Guérir les souffrances familiales*. Paris : Puf, 2004 : 629-36.
- Markle-Reid, M, Browne, G. Conceptualization of frailty in relation to older adults. *J Adv Nurs*, 2003, 44(1), 58-68.
- Massey, A. J. Medication-related issues associated with the management of dementia. *The ASHA Leader*, Nov.12-13, 2005.
- McCann, J.J., Hebert, L.E, Bienna, J.J., Morris, M.C., Evans, D.A. «Predictors of beginning and ending caregiving during a 3-year period in a biracial community. *Am J Public Health.*, October; 94(10). 2004, p. 1800–1806.
- McCormick, W.C. et al. Symptom patterns and comorbidity in the early stages of Alzheimer's disease. *J. Am. Geriatric. Soc.*, 1994, 42. 517-521.
- McCusker J et al. Delirium in older medical inpatients and subsequent cognitive and fonctionnal status: A prospective study. *CMAJ* 2001 p. 575 -583.
- McKeith IG, Ballard CG, Harrison RW. Neuroleptic sensitivity to risperidone in Lewy body dementia. *Lancet*. 1995;346:699.
- McKeith I, Del Ser T, Spano P, Emre M, Wesnes K, Anand R, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. *Lancet* 2000; 356:2031-6.
- McKeith G, Dickson, DW, Lowe, J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. *Neurology*. 2005;65: 1863.
- Meehan KM, Wang H, David SR, et al. Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia. *Neuropsychopharmacology*. 2002;26:494-504.
- Mega MS, Cummings JL, Fiorello T, Gornbein J. The spectrum of behavioral changes in Alzheimer's disease. *Neurology*. 1996;46:130-135.
- Michon, A., Weber, K., Gargiulo, M., Canuto, A., Giardini, U., Giannakopoulos, P. Le fardeau du soignant dans la démence: déterminants et stratégies d'intervention. *Schweizer Archiv für Neurologie und Psychiatrie*, 155, 4, 2004, p. 217-224.
- Miles SH, Irvine P. Deaths caused by physical restraints. *Gerontologist*. 1992;32:762-766.
- Montague, T. *Patients first : closing the health care gap in Canada*. John Wiley, Mississauga, Canada. 2004.
- Montague, T., Gogovor, A., Krelbaum, M. *Chronic Care and Disease Management: Why? Why Now?* Health Management Research Group. Communication personnelle. 2007.

Moretti et al. Cholinesterase inhibitor as a possible therapy for delirium in vascular dementia: A controlled, open 24-month study of 246 patients, *Am J of Alz Dis and Other Dementias*, 2004, 19, 6, 333-39.

Morris JC. The Clinical Dementia Rating (CDR): Current Version and Scoring Rules. *Neurology* 1993;43:2412-14.

Murray J, Schneider J, Banerjee S, Mann A. EURO CARE : a cross-national study of co-resident spouse carers for people with Alzheimer's disease : II--A qualitative analysis of the experience of caregiving. *Int J Geriatr Psychiatry* 1999 ; 14 : 662-7.

Nadeau, S. Le service de prévention des chutes et d'adaptations mineures du domicile. Bilan après deux années de régionalisation. ASSS-Mauricie/Centre du Québec. Direction de la santé publique. Québec. 2005.

Nagaratnam N, Lewis-Jones M, Scott D, Palazzi L. Behavioral and psychiatric manifestations in dementia patients in a community: caregiver burden and outcome. *Alzheimer Dis Assoc Disord*. 1998;12:330-334.

Narayan et al. Treatment of dementia with behavioral disturbance using divalproex or a combination of divalproex and a neuroleptic. *J. Clin. Psych.*, 1997, 58(8), 351-4.

Noblet-Dick, M., Kiesmann, M., Kaltenbach, G., Lang, P.O., Akkuzu, H., Martin-Hunyadi, C., Berthel, M. Evaluation par l'inventaire Neuropsychiatrique (NPI) des symptômes comportementaux et psychologiques aux différents stades de la maladie d'Alzheimer. *Revue de Gériatrie*, 29, 2004, 605-612.

Nyth AL, Gottfries CG. The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders. A Nordic multicentre study. *Br J Psychiatry* 1990;157:894-901.

O'Donnell M, Molloy DW, Rabheru K. *Dysfunctional behaviour in dementia: a clinician's guide*. Dundas, Ontario: New Grange Press; 2001.

Olin J, Schneider L. Galantamine for Alzheimer's disease. *Cochrane Database Syst Rev*. 2002;3:CD001747.

Olin JT, Fox LS, Pawluczyk S, Taggart NA, Schneider LS. A pilot randomized trial of carbamazepine for behavioral symptoms in treatment-resistant outpatients with Alzheimer disease. *Am J Geriatr Psychiatry* 2001;9:400-5.

Paddock, K., Hirdes, J.P. *Acute health care service use among elderly home care clients*. *Home Health Care Serv Q*. 22[1] : 2003, 75 à 85.

Pasquier, F. *Troubles du comportement, prospective*. In « *Les nouveaux défis de la maladie d'Alzheimer* », Editions Médigone, 2002, pp 204-6.

Paun O. Female Alzheimer's patient caregivers share their strength. *Holist Nurs Pract* 2004 ; 18 : 11-7.

Pearlin, L., J. Mullan, S. Semple, M. «Caregiving and the stress process : an overview of concepts and measures». *The Gerontologist*, 30(5), 1990, 583-594.

Petersen R.C. Mild Cognitive Impairment as a diagnostic entity. *J. Intern Med*, 2004, 256 (3): 183-94.

Pollock BG, Mulsant BH, Rosen J, Sweet RA, Mazumdar S, Bharucha A, et al. Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. *Am J Psychiatry* 2002;159:460-5.

Porstyeinsson et al. (2001). Placebo-controlled study of divalproex sodium for agitation in dementia, *Am. J. Ger. psych*, 2001;9, 58-66.

- Poulin de Courval, L., G elinas, I., Gauthier, S., Gayton, D., Liu, L., Rossignol, M., Sampal, J., Dastoor, D. Reliability and validity of the Safety Assessment Scale for people with dementia living at home. *Can J of Occ Therapy*, 73, 2, 2006, 67-75.
- Pruchno RA, Resch NL. Husbands and wives as caregivers : antecedents of depression and burden. *Gerontologist* 1989 ; 29 : 165-9.
- Rahkonen T, Eloniemi-Sulkava U, Rissanen S, Vatanen A, Viramo P, Sulkava R. Dementia with Lewy bodies according to the consensus criteria in a general population aged 75 years or older. *J Neurol Neurosurg Psychiatry*. 2003;74:720-724.
- Raina, P., O'Donnell, M., Schwellnus, H., Rosenbaum, P., King, G., Brehaut, J., Russell, D., Swinton, M., King, S., Wong, M., Wa;ter, S.D., Wood, E. «Caregiving process and caregiver burden : conceptual models to guide research and practice». *BMC Pediatrics*, 4(1), 2004, 1.
- Raynaud-Simon, A, Nutrition, d emences vasculaires et maladie d'Alzheimer. *Nutrition clinique et m etabolisme*, 2004, 18, 4, 181-188.
- Rayner, AV, O'Brien, JG, Schoenbachler, B. Behavior disorders of dementia: recognition and treatment. *Am Fam Phys*, 2006, 73(4).
- Reisberg B, Borenstein J, Salob SP, Ferris SH, Franssen E, Georgotas A. Behavioral symptoms in Alzheimer's disease: phenomenology and treatment. *J Clin Psychiatry* 1987;48(suppl):9-15.
- Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ. Memantine in moderate-to-severe Alzheimer's disease. *N Engl J Med*. 2003;348:1333-1341.
- Retz W, Rosler M, Sitzmann L, Becker T. Clozapine in treatment of neuropsychiatric diseases in the elderly. [German] *Fortschr Neurol Psychiatr* 1997;65:347-53.
- Rockwood K, MacKnight C. Assessing the clinical importance of statistically significant improvement in anti-dementia drug trials. *Neuroepidemiology*. 2001;20:51-56.
- Rockwood K, Mintzer J, Truyen L, Wessel T, Wilkinson D. Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial. *J Neurol Neurosurg Psychiatry*. 2001;71:589-595.
- Rockwood, K., Sing, X., MacKnight, C., Bergman, H., Hogan, D., McDowell, I., Mitnitski, A. A global clinical measure of fitness and frailty in elderly people. *CMAJ*, 173,5, 2005, 489-495.
- Rolfson, D et al. Validity and reliability of the Edmonton Frail Scale. *Publ elctr*. 2006, doi:10.1093/ageing/af1041.
- Roman, G.C., Tatemichi, T.K., Erkinjuntti T et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. *Neurology* Feb, 1 993;43(2):250-60.
- Rubenstein et al. Screening for under nutrition in geriatric practice : Developing the short-form Mini Nutritional Assessment (MNA-SF). *J. Geront.*, 56A, 2001, 366-377.
- Ruths S, Straand J, Nygaard HA, Bjorvatn B, Pallesen S. Effect of antipsychotic withdrawal on behavior and sleep/wake activity in nursing home residents with dementia: a randomized, placebo-controlled, double-blinded study: the Bergen District Nursing Home Study. *J Am Geriatr Soc*. 2004;52:1737-1743.
- Schneider LS, Pollock VE, Lyness SA. A meta-analysis of controlled trials of neuroleptic treatment in dementia. *J Am Geriatr Soc*. 1990;38:553-563.

Schneider LS, Tariot PN, Lyketsos CG, et al. National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer disease trial methodology. *Am J Geriatr Psychiatry*. 2001;9:346-360.

Schultz, R. Beach, S.R. «Caregiving as a risk factor for mortality – The caregiver health effects study». *JAMA*, 282(23), 1999. p.2215-2219.

Schultz, R., Martire, L.M. «Family caregiving of persons with dementia : prevalence, health effects and support strategies». *American Journal of Psychiatry*, 12(13), 2004, p. 240-249.

Scott et al. *Guide des meilleurs pratiques pour la prévention des chutes chez les aînés vivant dans la communauté*. Division du vieillissement et des aînés. Santé Canada. URL : www.hc-sc.gc.ca/seniors-aines.2001.

Sechi G, Agnetti V, Masuri R, et al. Risperidone, neuroleptic malignant syndrome and probable dementia with Lewy bodies. *Prog Neuropsychopharmacol Biol Psychiatry*. 2000;24:1043-1051.

Shankle et al. Low-dose propranolol reduces aggression and agitation resembling that associated with orbito-frontal dysfunction in elderly demented patients. *Alzheimer Dis. Ass. Disorder*, 1995, 9(4), 233-7.

Shelly, A.V., Colleen, J., Maxwell, D.B., Hogan, S.B., Patten, J.A., Johnson, L. Assessing medication adherence among older persons in community settings . *Can J Clin Pharmacol Vol 12 (1)*. 2005, 152-164.

Sherwood, P.R., Given, B.A., VON EYE, A. «Caregiver burden and depressive symptoms : analysis of common outcomes in caregivers of elderly patients». *Journal of aging and health*, 17(2), 2005, p. 125-147.

Shugarman, L.R., Fries, B.E., Wolf, R.S., Morris, J.N. Identifying older people at risk of abuse during routine screening practices. *J Am Geriatr Soc*. 51[1], 2003, 24-31.

Sink KM, Covinsky KE, Newcomer R, Yaffe K. Ethnic differences in the prevalence and pattern of dementia-related behaviors. *J Am Geriatr Soc*. 2004;52:1277-1283.

Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. *JAMA* 2005, 293:596-608.

Sival RC, Haffmans PM, Jansen PA, Duursma SA, Eikelenboom P. Sodium valproate in the treatment of aggressive behavior in patients with dementia: a randomized placebo controlled clinical trial. *Int J Geriatr Psychiatry*, 2002;17:579-585.

Small GW, Rabins PV, Barry PP, Buckholtz NS, DeKosky ST, Ferris SH, et al. Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. *JAMA* 1997;278:1363-71.

Snowden M, Sato K, Roy-Byrne P. Assessment and treatment of nursing home residents with depression or behavioral symptoms associated with dementia: a review of the literature. *J Am Geriatr Soc* 2003;51:1305-17.

Société Française de Gériatrie et Gérontologie. Les bonnes pratiques de soins en EHPAD. Sous la coordination de François Puisieux, 2007.

Steele C, Rovner B, Chase GA, Folstein M. Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease. *Am J Psychiatry*. 1990;147:1049-1051.

Stern Y, Tang MX, Albert MS, et al. Predicting time to nursing home care and death in individuals with Alzheimer disease. *JAMA*. 1997;277:806-812.

Stotsky B. Multicenter study comparing thioridazine with diazepam and placebo in elderly, nonpsychotic patients with emotional and behavioral disorders. *Clin Ther.* 1984;6:546-559.

Stoudemire A, Smith DA. OBRA regulations and the use of psychotropic drugs in long-term care facilities: impact and implications for geropsychiatric care. *Gen Hosp Psychiatry.* 1996;18:77-94.

Street JS, Clark WS, Gannon KS, et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial: the HGEU Study Group. *Arch Gen Psychiatry.* 2000;57:968-976.

Street JS, Clark WS, Kadam DL, Mitan SJ, Juliar BE, Feldman PD, et al. Long-term efficacy of olanzapine in the control of psychotic and behavioral symptoms in nursing home patients with Alzheimer's dementia. *Int J Geriatr Psychiatry* 2001;16(suppl 1):S62-70.

Sultzer DL, Gray KF, Gunay I, Wheatley MV, Mahler ME. Does behavioral improvement with haloperidol or trazodone treatment depend on psychosis or mood symptoms in patients with dementia? *J Am Geriatr Soc* 2001;49:1294-300.

Tariot PN, Cummings JL, Katz IR, Mintzer J, Perdomo CA, Schwam EM, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. *J Am Geriatr Soc* 2001;49:1590-9.

Tariot PN, Erb R, Podgorski CA, et al. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. *Am J Psychiatry.* 1998;155:54-61.

Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. *JAMA.* 2004;291:317-324.

Tariot PN, Ismail MS. Use of quetiapine in elderly patients. *J Clin Psychiatry* 2002;63(suppl 13):21-6.

Tariot PN, Schneider LS, Mintzer J, et al. Safety and tolerability of divalproex sodium in the treatment of signs and symptoms of mania in elderly patients with dementia: results of a double-blind, placebo-controlled trial. *Curr Ther Res Clin Exp.* 2001;62:51-67.

Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C. A 5-month, randomized, placebo-controlled trial of galantamine in AD: the Galantamine USA-10 Study Group. *Neurology.* 2000;54:2269-2276.

Taylor DH Jr, Sloan FA, Doraiswamy PM. Marked increase in Alzheimer's disease identified in medicare claims records between 1991 and 1999. *J Gerontol A Biol Sci Med Sci.* 2004;59:762-766.

Teri L, Logsdon RG, Peskind E, et al. Treatment of agitation in AD: a randomized, placebo-controlled clinical trial. *Neurology.* 2000;55:1271-1278.

Thomas P, Billon R, Lalloué F, Hazif Thomas C, Clément JP. Situation des aidants informels des déments vivants à domicile ou en institution. *L'étude Pixel. La revue francophone de gériatrie et de gérontologie* 2003 ; X : 273-80.

Thomas P, Chantoin-Merlet S, Hazif-Thomas C, Belmin J, Montagne E, Clément JP, et al. Complaints of informal caregivers providing home care for dementia patients : The PIXEL Study. *Int J Geriatr Psychiatry* 2002 ; 17 : 1034-47.

Thomas P, Clément JP, Hazif-Thomas C, Leger JM. Family, Alzheimer's disease and negative symptoms. *Int J Geriatr Psychiatry* 2001 ; 16 : 192-202.

- Thomas P, Hazif-Thomas C, Lalloué F, Popch B, Pariel S, Robcis I, et al. Qualité de vie du malade dément à domicile et qualité de vie de l'aidant. L'étude Pixel. *La revue francophone de gériatrie et de gérontologie* 2005 ; XII : 33-43.
- Thomas P, Hazif-Thomas C., Delagnes, V., Bonduelle, P., Clément, J.P. La vulnérabilité de l'aidant principal des malades déments à domicile. *Psychol NeuroPsychiatr Vieil*, 3,3, 2005, p. 207-220.
- Thomas P, Ingrand P, Lalloué F, Hazif-Thomas C, Billon R, Vieban F, et al. Reasons of informal caregivers for institutionalising dementia patients previously living at home : the Pixel study. *Int J Geriatr Psychiatry* 2004 ; 19 : 127-35.
- Thomas P. Entrée en institution des déments. L'étude Pixel. *Gerontologie et Société* 2005 ; 112 : 141-56.
- Thompson RL, Lewis SL, Murphy MR, Hale JM, Blackwell PH, Acton GJ, et al. Are there sex differences in emotional and biological responses in spousal caregivers of patients with Alzheimer's disease ? *Biol Res Nurs* 2004 ; 5 : 319-30.
- Tinetti, M.E. Preventing falls in elderly persons. *New England. J. Med.* 348, 1, 2003, 42-49.
- Treatment of agitation in older persons with dementia. Expert Consensus Panel for agitation in dementia. *Postgrad Med* 1998;spec no:1-88.
- Treatment of agitation in older persons with dementia: the Expert Concensus Panel for Agitation in Dementia. *Postgrad Med.* 1998;Spec No:1-88.
- Treolar, A., Beck, S., Paton, C. Administering medicines to patients with dementia and other organic syndromes. *Adv. Psych. Treatment*, 7, 2001, 444-50.
- Trinh NH, Hoblyn J, Mohanty S, Yaffe K. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. *JAMA.* 2003;289:210-216.
- Troisième conférence canadienne de consensus sur le diagnostic et le traitement de la démence. *Alzheimer's & Dementia*, 3. 2007.
- Vedhara K, Shanks N, Anderson S, Lightman S. The role of stressors and psychosocial variables in the stress process : a study of chronic caregiver stress. *Psychosom Med* 2000 ; 62 : 374-85.
- Wagner AK, Zhang F, Soumerai SB, et al. Benzodiazepine use and hip fractures in the elderly: who is at greatest risk? *Arch Intern Med.* 2004;164:1567-1572.
- Walker Z, Grace J, Overshot R, et al. Olanzapine in dementia with Lewy bodies: a clinical study. *Int J Geriatr Psychiatry.* 1999;14:459-466.
- Wancata J, Windhaber J, Krautgartner M, Alexandrowicz R. The consequences of non-cognitive symptoms of dementia in medical hospital departments. *Int J Psychiatry Med.* 2003;33:257-271.
- Ward JH. Hierarchical grouping to optimize an objective function. *J Am Stat Assoc* 1963; 58 : 236-44.
- Wilcock GK. Dementia with Lewy bodies. *Lancet.* 2003;362:1689-1690.
- White, HK. Nutrition in advanced Alzheimer's disease. *NC Med J*, 2005, 66(4), 307-312.
- Wilkinson et al. Donepezil in vascular dementia: a randomized placebo-controlled study. *Neurology*, 2003, 61, 479-86.

Wiseman SV, McAuley JW, Freidenberg GR, Freidenberg DL Hypersexuality in patients with dementia: possible response to cimetidine. *Neurology* 2000 May 23;54(10):2024.

Yaffe K, Fox P, Newcomer R, Sands L, Lindquist K, Dane K, et al. Patient and caregiver characteristics and nursing home placement in patients with dementia. *JAMA* 2002 ; 287 : 2090-7.

Zarit SH, Gaugler JE, Jarrott SE. Useful services for families : research findings and directions. *Int J Geriatr Psychiatry* 1999 ; 14 : 165-77.

Zarit SH, Reever KE, Bach-Peterson J. Relatives of the impaired elderly : correlates of feelings of burden. *Gerontologist* 1980 ; 20 : 649-55.